ERBB2 and cancer: Since the 2000s, ACT therapy has continued to evolve with advances in gene editing technologies, such as CRISPR‐Cas9 opening up new possibilities for enhancing T‐cell function and expanding its application to various types of cancers and infectious diseases as well as other immune cells, such as CAR‐M (CAR‐expressing monocytes/macrophages),5 CAR‐NK (CAR‐expressing natural killer cells)6 and even CAR‐Neu (CAR‐expressing neutrophils).7